Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow ERAS by emailGet an email when ERAS pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ERAS, unsubscribe in one click. Privacy
📣 What ERAS Says Is Next
second half of 2027 · “Phase 3 pivotal trial in RASm NSCLC expected to initiate in the second half of 2027 to the first half of 2028 BOREALIS-1: Phase 1 trial for ERAS-4001 (potential first-in-class pan-KRAS inhibitor)”
Company press release, Aug 11, 2026 · SEC filing
in 2027 · “Phase 3 pivotal trial in 1L PDAC expected to initiate in 2027”
Company press release, Aug 11, 2026 · SEC filing
first half of 2027 · “Potentially registration-enabling trial in 2L+ NSCLC expected to initiate in the first half of 2027”
Company press release, Aug 11, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full ERAS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ERAS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.